APOBEC3B and neoplasm: Whereas the priming of T cells reactive only against de novo neoepitopes will allow immune clearance only of APOBEC3B-modified tumor cells themselves, priming of T cells by heteroclitic neoepitopes will allow for bystander clearance of both APOBEC3B-modified, as well as parental, unmodified tumor cells.